Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1, 3, 4-thiadiazoline analogue in tumor cells. Issue 7 (August 2018)

• Record Type: Journal Article
• Authors: Giantulli, Sabrina; De Iuliis, Francesca; Taglieri, Ludovica; Carradori, Simone; Menichelli, Giusi; Morrone, Stefania; Scarpa, Susanna; Silvestri, Ida
• Is Part Of: Anti-cancer drugs. Volume 29:Issue 7(2018)
• Publication Date: 2018-08
• Subjects: antiproliferative activity -- apoptosis -- Eg5 inhibitors -- K858 -- thiadiazolines; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000641
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Tumors are complex and heterogeneous but, despite this, they share the ability to proliferate continuously, irrespective of the presence of growth signals, leading to a higher fraction of actively growing and dividing cells compared with normal tissues. For this reason, the cytotoxic antimitotic treatments remain an important clinical tool for tumors. Among these drugs, antitubulin compounds constitute one of the most effective anticancer chemotherapies; however, they cause dose-limiting side effects. Therefore, it is still necessary to develop compounds with new targets and new mechanisms of action to reduce side effects or chemoresistance. Mitosis-specific kinesin Eg5 can represent an attractive target for discovering such new anticancer agents because its role is fundamental in mitotic progression. Therefore, we analyzed the effects induced by an inhibitor of kinesin Eg5, K858, and by its 1, 3, 4-thiadiazoline analogue on human melanoma and prostate cancer cell lines. We found that both compounds have an antiproliferative effect, induce apoptosis, and can determine a downmodulation of survivin.